RxDoctor Payments Data
★ My doctorsLook up a doctor →

Robert Coleman

Gynecologic Oncology · Houston, TXNPI 1669570685

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $576,421 of the $864,078 with a category attached, or 66.7%. 46 manufacturers reported payments, led by Merck at 26.5% of the total. Among gynecologic oncology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$864,078in general payments, 2019–2025

Across 561 payments — averaging $1540.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$229K
  • GSK$127K
  • Astrazeneca UK Limited$82K
  • AstraZeneca$72K
  • Eisai Inc.$40K
  • Clovis Oncology, Inc.$28K
  • plus $286K from 40 others
$2,528,637in research payments, 2019–2025

Across 49 payments — averaging $51,605 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Amgen$1.8M
  • Merck$661K
  • Clovis Oncology, Inc.$72K
  • AbbVie$5K
  • F. Hoffmann-la Roche AG$1K
  • Seagen Inc.$391

What the payments were for

  • Consulting fees$576,42167%
  • Speaking & faculty fees$148,99117%
  • Grants$3000%
  • Travel & lodging$125,24514%
  • Food & beverage$12,9221%
  • Education$1990%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Merck111$228,844
GSK62$127,451
Astrazeneca UK Limited34$81,698
AstraZeneca57$72,044
Eisai Inc.22$40,069
Clovis Oncology, Inc.31$28,213
AbbVie30$25,750
EMD Serono Research & Development Institute, Inc.5$23,437
Seagen Inc.23$20,798
Biontech SE8$18,776
F. Hoffmann-la Roche AG8$17,093
Alkermes, Inc.7$14,419
Genentech, Inc.4$12,079
Novocure GmbH3$11,565
Aadi Bioscience, Inc.6$11,546
Tesaro, Inc.31$11,205
Regeneron8$10,122
Corcept Therapeutics5$9,471
Chugai Pharmaceutical Co., Ltd.2$7,700
Gilead7$7,208
Myriad Genetic Laboratories, Inc.5$7,200
Pfizer2$7,100
Genmab U.S., Inc.8$6,849
Novocure Inc.16$6,643
Jazz Pharmaceuticals Inc.2$6,000
Eisai CO., LTD.2$5,775
Immunocore Limited2$4,485
Daiichi Sankyo Inc.9$4,299
Beone Medicines USA, Inc.3$4,149
E.r. Squibb & Sons, L.L.C.4$4,050
Beigene USA, Inc.2$3,900
Deciphera Pharmaceuticals Inc.2$3,600
Taiho Oncology, Inc.5$2,953
Bayer1$2,850
Karyopharm Therapeutics Inc.12$2,752
Novartis3$2,638
Eli Lilly1$2,625
Immunogen, Inc.5$2,181
Epizyme, Inc.1$1,500
Incyte Corporation2$1,086
Genentech USA, Inc.4$854
Radius Health, Inc.1$656
Pharmaand GmbH2$224
Ipsen Biopharmaceuticals, Inc1$119
Johnson & Johnson1$80
Sirtex Medical Inc1$25

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$864,078 in reported general payments places this provider in the 95th percentile of 135 gynecologic oncology providers in Texas.

See all gynecologic oncology providers in Texas →

Other gynecologic oncology in Houston

See the full list for Texas →

Where these figures come from

Is this you, or does something look wrong? →